Introduction
Experience with unrelated allogeneic umbilical cord blood (UCB) transplantation in the non-myeloablative setting has been limited previously because of concerns of recipient rejection of a one-unit graft with low nucleated cell content for most adult patients. [1] [2] [3] [4] Two-unit UCB graft infusion has been explored in an attempt to overcome these graft cell dose limitations for adult patients in both the myeloablative, [5] [6] [7] and non-myeloablative setting. [8] [9] [10] [11] [12] Potential UCB immunological and stem cell homing mechanisms underlying engraftment of the dominant unit in patients treated with two units are not fully understood. [13] [14] [15] [16] The minimum threshold for cryopreserved total nucleated cell (TNC) doses to allow engraftment of one-UCB graft in adult hematology patients has not been clearly determined in the reduced intensity conditioning (RIC) setting; and is potentially influenced by HLA and Killer Inhibitory Receptor disparity, ABO mismatch, among other factors. [17] [18] [19] Current recommendations for UCB TNC threshold cell doses for adult patients in the myeloablative setting is X2.5 Â 10 7 /kg recipient weight, rendering favorable outcomes similar to that observed in patients receiving standard BM and mobilized PBPC grafts from adult donors. [20] [21] [22] [23] [24] Several retrospective series have observed low relapse rates in hematological malignancy patients with two units compared with one-UCB graft infusion. 21, 25, 26 Interpretation of these data is challenging, however, because of variations in the preparatory regimens used, patient selection differences including marked age variation, and modifications in supportive care including GvHD prophylaxis and anti-thymocyte globulin (ATG) administration during the course of these studies; factors that may contribute to the benefits otherwise attributed specifically to the infusion of one-vs two-UCB grafts.
The purpose of this study was to test the feasibility, safety and efficacy of infusing two-UCB units into adult patients treated uniformly with the same RIC, GvHD prophylaxis and supportive care regimen; and determining whether rates and kinetics of engraftment, acute GvHD incidence, relapse rates and survival may differ from the infusion of one-UCB unit. We also examined the influence, if any, of UCB graft infused TNC, CD34 þ hematopoietic progenitors, natural killer cells and T-cell doses on procedure outcomes including: OS, allogeneic engraftment and EFS. We outline herein the analyses of this clinical trial.
Methods

Transplant protocol and patient eligibility
The Institutional Review Board of Case Western Reserve University/University Hospitals Case Medical Center approved the clinical protocol: registered at http://clinical trials.gov (NCT00054236). Written informed consent was obtained from all patients. Eligibility criteria included the following: (i) histological confirmation of a hematological malignancy with high-risk features such as early relapse, high-risk cytogenetic abnormalities or failure of standard treatments; (ii) patients unable to tolerate fully myeloablative conditioning either due to advanced age (455 years), extensive prior treatment or co-morbid diseases such as suboptimal visceral organ function, or recent lifethreatening infection; (iii) lack of available 5/6 or fully HLA-matched-related donor and (iv) Karnofsky performance status X70%, and adequate organ function (creatinine clearance 440 mL/min; AST/ALT o4 Â upper limit of normal; total serum bilirubin o2 mg/dL; cardiac ejection fraction 440%; forced vital capacity, forced expiratory volume in 1 second and diffusing capacity of lung for carbon monoxide 460% of predicted for age on pulmonary function testing). Patients were not eligible if they had uncontrolled infection at time of enrollment, had active central nervous system disease, chronic myeloid leukemia in blast crisis without complete response to reinduction chemotherapy, acute leukemia in refractory relapse, extensive BM fibrosis or were seropositive for HIV.
Conditioning regimen, graft selection and supportive care RIC consisted of fludarabine 35 mg/m 2 /day i.v. over 30 min daily for 5 days on days T-8 to T-4 prior to UCB infusion (day 0), cyclophosphamide 1 gm/m 2 /day i.v. over 2 h on days T-3 and T-2 with mesna 1 gm/m 2 each day, horse ATG (Pharmacia-Upjohn, Kalamazoo, MI, USA) 30 mg/kg/day i.v. on days T-3 and T-2 and TBI 200 cGy on day T-1. Preparative regimen dosing was based on actual weight unless the actual weight was X125% of the ideal weight. In these patients, the adjusted body weight (ideal weight þ 25% (difference actual-ideal weight)) was used.
Trial design specified selection of UCB grafts to be matched at 4/6 HLA loci or better to the recipient and minimum 3/6 match to each other. HLA DNA typing specified the match at the antigen level for HLA-A and HLA-B loci, and allele level at DRB-1 loci. Blanks were interpreted as homozygous for that locus and disparities were scored accordingly. The algorithm for unit selection specified: (i) the best HLA-matched unit, with (ii) the highest cell dose. Selection criteria for one-UCB unit required a cryopreserved nucleated cell dose X2.5 Â 10 7 /kg recipient weight. Selection criteria for two-UCB units required a combined cell dose X3.0 Â 10 7 /kg (X1.5 Â 10 7 /kg each unit). The total UCB nucleated cell dose (cryopreserved and infused) was calculated on the patient's actual body weight. All UCB grafts were obtained from FACT or AABB accredited banks. A backup graft source was identified for all patients enrolled on the study. For those patients who had received prior hematopoietic cell transplants, HLA typing was re-verified by STR analyses to determine if the patient's blood genotype was their own HLA typing or the typing of donor of the antecedent transplant. The graft was then selected to be a 4/6 or better to the verified HLA typing.
Supportive care included administration of granulocyte CSF (Amgen, Thousand Oaks, CA, USA) at a dose of 5 mg/kg/day s.c. starting day T þ 7 after UCB infusion until ANC 42500/ mL was attained for 3 consecutive days. GvHD prophylaxis consisted of (i) CYA (Sandimmune, Novartis, East Hannover, NJ, USA) starting at 3 mg/kg/day i.v. or orally in two divided doses day TÀ2 to T þ 60 then tapered in the absence of GvHD and discontinued by day T þ 100, and (ii) mycophenolate mofetil (Cellcept, Hoffmann-La Roche Ltd, Basel, Switzerland) i.v. or orally 45 mg/kg/day (in three divided doses) day T þ 1 to T þ 30. All patients received antimicrobial, fungal and viral prophylaxis as described previously. 23 
Chimerism
Recipient chimerism studies were performed on PBMC samples weekly Â 4, monthly for the first 6 months and at 9, 12, 14, 16, 18, and 24 months after transplant. Analyses were performed using either quantitative PCR for STR regions for sex-matched grafts and two-unit grafts or FISH for the Y chromosome in patients receiving a single-sexmismatched graft.
UCB graft infusion and flow cytometric analyses UCB grafts were thawed and washed according to the standard procedures, 27 and infused within 60 min of thawing. After thawing, an aliquot was obtained for the following tests: viable nucleated cell count (by trypan blue dye exclusion), enumeration of CD34 þ cell and lymphocyte populations by flow cytometry, colony forming unit methylcellulose assays and bacterial and fungal cultures. A volume of 0.5 mL aliquot of each infused graft was analyzed by flow cytometry for hematopoietic progenitors (CD34 þ ) and lymphocyte popula-
. Approximately 25 000-30 000 total events were analyzed on a BD FACS Calibur (Franklin Lakes, NJ, USA) for each UCB unit aliquot. UCB graft post-thaw aliquot CD34 þ and lymphocyte fluorescence-activated cell sorting percentages were multiplied by enumerated infused viable nucleated cells and divided by actual patient weight to calculate the cell dose/ kg for each cell population of interest infused in each consecutive study patient.
Statistical analysis
Study endpoints included: hematopoietic recovery, donor engraftment failure, severe grade III/IV acute GvHD, grade
Umbilical cord blood transplant in adults TL Kindwall-Keller et al III or IV infusion-related toxicity and day þ 100 OS. Interim analysis was performed following the accrual of every six patients to each cohort (one vs two units) to monitor the safety of the trial. Stopping rules were as follows: (i) grade III or IV infusion-related toxicity 420%, (ii) hematopoietic recovery failure rate 415%, (iii) engraftment failure rate 410%, (iv) grade III/IV acute GvHD rate 420% and (v) day þ 100 OS o60% in either group. Statistical comparisons between the one-unit and two-unit groups for GvHD, EFS and OS were a planned as part of the trial design.
Secondary study endpoints included OS and EFS, incidence and rate of allogeneic donor engraftment and graft failure, kinetics of neutrophil and platelet recovery, incidence of acute and chronic GvHD, treatment-related mortality (TRM) and disease relapse. OS was measured from the date of transplantation (T ¼ 0) to the date of death and censored at the date of last follow-up for survivors. EFS was measured from the date of transplantation to the date of death or relapse and censored at the date of last follow-up for survivors without relapse. OS and EFS distributions, hematopoietic recovery (ANC 4500/mL, platelets 420 000/mL) and engraftment (chimerism 460%) were estimated by the Kaplan-Meier methods and the differences in survival and engraftment between patients who received one vs two units were examined by log-rank test. TRM was defined as death without relapse and the cause of death related to the transplantation. The association between number of UCB units and TRM was examined by w 2 test/Fisher's exact test. Patient and graft characteristics examined by descriptive analysis included as follows: age, actual weight, gender, number of UCB units infused, underlying disease, acute GvHD, chronic GvHD, engraftment parameters (chimerism), hematopoietic recovery (ANC and platelet recovery) and UCB graft cell dose variables (TNC, CD3
þ ) between one-unit and two-unit UCB groups were examined by t-test/Kruskal-Wallis test. Neutrophil recovery was defined by an ANC 4500 cells/mL for three consecutive days and platelet recovery was defined as the first day of 7 consecutive days of 420 000 platelets/mL, unsupported by transfusions. The cumulative incidences of neutrophil and platelet recovery were calculated to account for competing risks. 28 Primary engraftment failure was defined as failure to restore donor hematopoiesis by day 42. Secondary engraftment failure was defined as a permanent loss of engraftment previously documented by donor chimerism on two separate occasions.
Effects of graft cell subpopulations including CD34
neg natural killer cells and TNC populations on EFS, OS and time to engraftment were evaluated by the Cox proportional hazard model. For those patients receiving two-UCB units the graft characteristics including cell populations of the predominating unit were used to examine effects, if any, on EFS, OS and engraftment. The effects of the number of UCB units infused and infused cell dose variables (TNC, CD3 þ , CD34 þ and CD56 þ CD3 neg ) on relapse were examined by multivariate logistic regression. Patients were evaluated daily for acute GvHD while hospitalized with data entry of highest stage each week and at subsequent weekly outpatient visits thereafter. Using binary distribution with confidence intervals (CIs) based on Wilson's method, 29 acute GvHD and chronic GvHD incidences were estimated. The association between the number of UCB units and acute GvHD was examined by univariate logistic regression.
Results
Patient and graft characteristics
All consecutive eligible study patients were included in the analyses. During the time period 9/2003 to 1/2010, 50 eligible patients were consecutively consented and enrolled on protocol, including 17 females (34%) and 33 males (66%) with a median age of 53.5 (range 21-71) years ( Table 1 ). The median patient weight was 84.3 (range 52-122) kg. The weight difference between the two groups A total of 27 patients were transplanted with one-UCB unit (54%) and 23 patients received two units (46%; Table 2 ). A total of 40 (54.8%) of the 73 transplanted units were matched at 4/6 HLA loci to the patient. In the case of patients who received two units, the units were matched at least 4/6 to the patient and a minimum 3/6 to each other (3/6 n ¼ 4, 4/6 n ¼ 8, 5/6 n ¼ 7, 6/6 n ¼ 4). A total of 46 patients demonstrating donor engraftment (four patients had no dominant unit) were evaluated for infused graft TNC dose, CD3
þ , CD34 þ and CD56 þ CD3 neg cell doses. Patients who were transplanted with one-UCB unit received higher numbers of CD34
þ CD3 neg cells (P ¼ 0.01), and TNC (Po0.0001) per actual body weight compared with the predominate unit in patients receiving a two-unit UCB transplant (Table 2) . There was no difference in the number of infused CD3 þ graft T-cells between the two groups (P ¼ 0.43).
Allogeneic engraftment and neutrophil recovery
The majority of study patients (36 patients) demonstrated predominant UCB donor engraftment by chimerism analysis on or before day T þ 42 ( Figure 1 ; Table 3 ). All patients demonstrating predominant donor chimerism (460%) at early time points went on to attain full donor chimerism ( Figure 1 ). Cumulative engraftment rate by donor chimerism at 100 days was 73.8% (95% CI: 0.61-0.85). No differences were seen in the cumulative rates of attaining donor chimerism at day 100 between the two groups; 72.4 in the one-unit group and 75.2% in the twounit group (P ¼ 0.95; Figure 2a ). Median time to attain donor chimerism 460% was 21 days (95% CI: 17-28 days). A total of 12 patients (25%) had donor engraftment failure by chimerism, 7 in the one-unit group and 5 in the two-unit group. Engraftment by chimerism was not evaluable in two patients, one patient in each group, due to early death (T þ 16 and T þ 27). All engrafting patients in the two-unit group showed early predominance of one-UCB unit with no stable mixed chimerism identified. The four patients in the two-unit group who did not have a dominant unit identified by chimerism demonstrated primary graft failure. Late engraftment (442 days) was seen in one patient in the two-unit group. Of the 36 patients who achieved predominant donor chimerism, 3 patients demonstrated temporary decreases to o60% donor chimerism, but regained predominant donor chimerism at a later date. Secondary graft failure occurred in two patients Table 2 Graft cell doses and HLA matching Umbilical cord blood transplant in adults TL Kindwall-Keller et al in the one-unit group attributed to treatment for CMV infection and an unknown etiology.
At day 100, 89.8% (95% CI: 0.80-0.96) of patients on this study recovered either autologous or donor ANC 4500/mL for at least 3 consecutive days, 88.4% in the oneunit group and 91.3% in the two-unit group (Figure 2b ). There was no significant difference in time to ANC 4500/ mL recovery between the two groups (P ¼ 0.99). The median time to neutrophil recovery was 24 days (95% CI: 22-28 days; mean 27.7 days), 25 days in the one-unit group and 23 days in the two-unit group (mean 27.9 and 26.3 days, respectively). Failure of neutrophil recovery occurred in six patients (12.0%), four patients in the one-unit group (1 early death) and two patients in the two-unit group. The median time to platelet recovery was 45 days (95% CI: 38-56 days; mean 58.1 days), 38.5 days in the one-unit group and 57 days in the two-unit group (mean 46.2 and 68.2 days, respectively). The rate of platelet engraftment for both the one-unit and two-unit groups was 81.3% at 100 days (95% CI: 0.69-0.91). No differences were noted comparing the one-unit group (90.4%) and the two-unit group (71.1%; P ¼ 0.08) at 100 days (Figure 2c ). Nine patients (18.0%) failed to engraft their platelets, four in the one-unit group (1 early death) and five in the two-unit group (one early death). A total of 46 patients were included in correlation analyses of graft cell doses and engraftment by predominant donor chimerism or ANC 4500/mL. There was no significant association of day to attain predominant chimerism or ANC 4500/mL with infused UCB graft TNC (P ¼ 0.84, 0.06), CD3
.10) cells using the dominant unit in two-unit recipients.
Survival and TRM
The Kaplan-Meier estimates for OS and EFS are depicted in Figures 3a-d . OS at 3 months was 88.9 in the one-unit group and 87.0% in the two-unit group. The 3-year OS and EFS for all patients were 37.6 and 32.4%. Medians of OS and EFS were 14.3 and 9.9 months. Three-year OS and EFS were 35.9 and 28.6% for the one-unit group and 39.1 and 39.1% for the two-unit group, respectively (Table 3) . OS and EFS at 60 months was 26.2% and 28.6% for the one-unit group, and 39.1 and 39.1% for the two-unit group. There was no difference between the two groups in OS and EFS (P ¼ 0.86 and 0.71). For OS, the hazard of dying for patients infused with two units was 11% higher than those infused with one unit after adjustment for the effects of age, gender and disease type, although the difference was NS (P ¼ 0.76). Similarly, the hazard ratio for EFS comparing two to one unit was 1.26 (P ¼ 0.52) after controlling the effects of age, gender and disease type. There was no correlation in 46 evaluable patients between the UCB graft TNC (P ¼ 0.84, 0.62
.23) cells infused, and OS or EFS (using the dominant unit in the two-unit recipients). The median follow-up for the entire group was 14.3 months (range 0.5-80 months). For those patients surviving (n ¼ 16), the median follow-up was 38 months (range 18-80 months). Early (o100 days) TRM was not seen in the one-unit group. Late TRM (n ¼ 100 days) occurred in three patients (11.1%) with two of the three patients dying from transplant-related causes after day 180 (Table 3 ). In the two-unit group, 7 of 23 patients (30.4%) died from nonrelapse causes, three before day 100 and one patient each on day 132 and day 270. The remaining two patients died at 41 year from complications related to transplantation (Table 4 ). There was no association between number of UCB units transplanted and overall TRM (P ¼ 0.16). No grade III or IV UCB infusion-related toxicities were seen in either the one-unit group or the two-unit group. Umbilical cord blood transplant in adults TL Kindwall-Keller et al Relapse and graft vs host disease incidence A total of 16 (59.3%) patients in the one-unit group relapsed, compared with only 7 (30.4%) patients in the twounit group (P ¼ 0.045; Table 3 ). The number of UCB units infused was a significant predictor for relapse by univariate analysis. The odds of relapsing for patients with one unit were 5.5 times higher than that for those receiving two units (P ¼ 0.013) after adjustment for confounders by multivariate analysis. None of the UCB graft cell dose variables (TNC, CD3 þ , CD34 þ and CD56 þ CD3 neg ) were significant predictors of relapse for either the one-or two-unit groups. Of four patients who had received HLA 3/6-matched one units (match criteria of high resolution class II DRB1 and low-resolution class I molecular typing), two are alive without disease recurrence, one patient each had progressive disease and autologous recovery followed by relapsed disease.
The rate of grade II-IV acute GvHD was 44.9% (95% CI: 0.32-0.59) in the two groups and the rate of grade III acute GvHD was 18.4% overall (95% CI: 0.10-0.31). Grade III acute GvHD was observed in 5 of 26 (19.2%) patients in the one-unit group and 4 of 23 (17.4%) in the two-unit group (Table 3) . No patient demonstrated grade IV acute GvHD. All patients were followed for 1 year for chronic GvHD evaluation. Chronic GvHD was observed in 5 of 23 (4 limited, 1 extensive; 21.7%) evaluable one-unit patients, and 5 of 19 (3 limited, 2 extensive; 26.3%) evaluable two-unit patients. The overall rate of chronic GvHD for all study patients was 23.8% (95% CI: 0.13-0.39). There was no significant association between the number of UCB units infused with occurrence of either acute GvHD (P ¼ 0.87) nor chronic GvHD (P ¼ 0.73).
Discussion
To our knowledge, this study is the first prospective investigation directly comparing a one-UCB unit vs twounit approach in adult hematological malignancy patients treated with uniform RIC and supportive care including acute GvHD prophylaxis. Published work to date has included retrospective and more recently prospective studies supporting the administration of two units in adult patients in the myeloablative and RIC setting. 5, 8, 11, 30 Our study design used the availability of a one-UCB unit of specified HLA match and nucleated cryopreserved cell dose (X2.5 Â 10 7 /kg) as biological assignment to one-vs two-unit UCB transplantation. Minimum required combined TNC dose of X3.0 Â 10 7 /kg was similar to previously reported requirements for two-unit recipients. 8, 13 However, as the threshold cell dose in the RIC setting has not been established, we chose a target dose of X2.5 Â 10 7 /kg above which patients were eligible for one-unit transplantation, based on previous reports identifying safety in the myeloablative setting. The target cell dose selected is lower than minimum threshold cell doses previously reported by other investigators in two-unit studies in adults treated with non-myeloablative conditioning. 9, 13, 31 Furthermore, this lower threshold cell dose allowed a larger proportion of study patients to proceed to transplant with a one-unit graft. These observations may allow an adult patient lacking two-UCB units of specified HLA match and cell content to proceed to transplantation with anticipated survival similar to that of two-unit recipients.
Brunstein et al. 10 reported the largest single-institution series to date including 110 patients who had received UCB grafts after non-myeloablative conditioning with 85% of patients who had a two-unit UCB graft. A total of 35% of patients in this study were treated with ATG to reduce risk of graft rejection, which correlated with reduced risk of acute GvHD and higher TRM. Important challenges to analyses of clinical trials published to date include variance in patient selection, a potential lack of uniformity in patient characteristics in those receiving one vs two units with a large proportion of one-unit recipients being pediatric patients, as well as changes over time in conditioning and GvHD prophylaxis including ATG administration.
The patients enrolled in this study are reflective of an adult hematology practice, including the predominance of myeloid leukemia over lymphoid malignancy, and are comparable to other reports in terms of age and weight range. 20, 32 Of note, most patients included in reports on RIC outcomes with conventional adult donor and UCB grafts, had either no or prior autologous hematopoietic cell transplantation. 9, 10, 33, 34 Our study patient population had extremely high-risk (therapy-related myeloid neoplasm, secondary AML) disease and was heavily pre-treated, including 450% of patients receiving prior autologous or allogeneic transplantation, implicating a possible higher risk of relapse-and non-relapse mortality. Despite this high risk, heavily pretreated patient population, EFS at 3 years was 28.6% in the one-unit group and 39.1% in the two-unit group and 5-year EFS was 28.6% in the one-unit group and 39.1% in the two-unit group. These data support the use of RIC and UCB allogeneic transplantation as safe and effective treatment in these patients with advanced disease and extensive prior therapy. Additionally, these data compare favorably to previous single-institution trials 9, 10 and larger retrospective series. 20, 32 Recent data published by the National Marrow Donor Program summarize transplant outcomes in adults treated with RIC and conventional adult-derived graft sources and show a 5-year OS of 23%. 35 A major concern for UCB transplant safety and efficacy for adult patients is the limited TNC and CD34 þ progenitor cell content in the graft, generally a log lower than adult-derived grafts. [36] [37] [38] Several studies have shown neutrophil engraftment after UCB transplantation correlating with graft TNC dose, 39, 40 CD34 þ cell dose, 13, 41, 42 CD3 þ cell dose 5, 13 and CD8 þ cell dose. 42 However, the influence of these graft cell populations is not seen consistently across all trials. CD34 þ UCB graft cell dose has also been observed to correlate with EFS, OS and lower TRM in some studies. From these studies the threshold of TNC dosing for UCB transplantation in the RIC setting has not been firmly established. We observed no differences in cumulative rates of attaining predominant donor chimerism at day 100 in this study, which were 72.4% in the one-unit group compared with 75.2% observed in the two-unit group. No differences were seen between the two groups in rates and kinetics of neutrophil and platelet engraftment. Additionally, we did not detect any statistically significant influence of TNC, CD34 þ or CD3 þ UCB graft infused cell dose on engraftment or survival. This observation is consistent with the study by Brunstein et al., 10 but differs from that reported in one-and two-unit UCB transplantation in the myeloablative setting.
5,21
Infusion of two-UCB units did however significantly impact on the relapse risk in this high-risk patient population with one-unit recipients having a relapse risk significantly higher than two-unit recipients, suggesting strong graft vs malignancy effect of two-unit UCB infusion as reported in prior retrospective studies. 21, 25 A total of 16 (59.3%) patients in the one-unit group in this study notably relapsed, compared with only 7 (30.4%) patients in the twounit group (P ¼ 0.045) in this study cohort of predominantly high risk or recurrent AML patients. Other investigators including Verneris et al. 25 noted that relapse was significantly lower for early stage (first or second CR) patients who received two-UCB units (RR 0.5, Po0.03) in 177 acute leukemia patients treated with myeloablative conditioning. The benefit of stronger graft vs lymphoma effect has also been reported by the Eurocord-Netcord and lymphoma working party of the European Group for Blood and Marrow Transplantation in 104 adult patients treated with one-or two-unit UCB after RIC with lower risk of relapse observed in recipients of two-unit UCB (P ¼ 0.03). 21 Consistently, one-UCB unit predominates in transplant recipients receiving two or more UCB units 8, 13, 43 usually by 4-6 weeks after transplant. Infusion of the nonengrafting unit may augment UCB engraftment via immune activation and/or inhibition of recipient-mediated immune rejection. 44 Because RIC transplantation depends on the 'allogeneic effect' to eliminate malignancy, each UCB unit represents an intact immune system with potential donor-recipient and donor-donor interactions that may render additional benefits of two-unit infusion, including enhanced graft vs malignancy effects.
UCB transplantation, despite frequent HLA-mismatch, carries a surprisingly low risk for acute and chronic GvHD; 24, 45 this risk could be conceivably higher in twounit recipients as reported previously. 10, 11 The combined rate of grade II-IV acute GvHD in this study was 44.9% in the two groups. Grade III acute GvHD rate was only 18.4% and no patient demonstrated grade IV disease. The incidence of chronic GvHD was only 23.8%. We observed no significant association between the number of UCB units infused and occurrence of either acute or chronic GvHD. These observations may be attributable in part to administration of ATG to all study patients in this series.
This single-institution feasibility study suggests that two-UCB transplantation elicits stronger graft vs malignancy effects in high-risk adult patients with primarily myeloid leukemia. Nevertheless, one-unit UCB transplantation at a threshold nucleated cell dose exceeding 2.5 Â 10 7 /kg recipient weight remains a valid treatment option with equivalent survival rates for patients lacking two-UCB units of specified HLA match and cell doses previously reported. Although similar results have been reported in prior retrospective analyses by other groups, the data in this prospective study strengthen these observations: for example, lower relapse risk after the infusion of two-UCB units, and similar survival outcomes in those transplanted with an adequate one or two units if one adequate unit is not available. There are also some differences: GvHD may not be increased in recipients of two units, and graft cell dose may not be a risk factor for OS or EFS comparing the two groups. Whether limited patient numbers and/or length of follow-up may underlie these differences, there are no prospective studies reported to date with UCB directly comparing one-vs two-unit infusion in the setting of RIC. Given the small numbers of patients, prolonged accrual time and the heterogeneity of the patient population in this study, definitive conclusions should be taken cautiously. Further studies are needed in larger multi-institutional prospective trials: (i) to more firmly establish the minimum safe threshold dose for one-unit UCB in adult patients treated with RIC and (ii) to identify key parameters for graft selection in the two-UCB unit setting that may contribute to enhanced graft vs malignancy effects confirmed in this prospective single-institution study.
